* known hypersensitivity to hcq or other 4-aminoquinoline compounds * known hypersensitivity to azithromycin or other azalide or macrolide antibiotics * currently hospitalized * signs of respiratory distress prior to randomization, including respiratory rate \>24 * current medications include hcq * concomitant use of other anti-malarial treatment or chemoprophylaxis * history of retinopathy of any etiology * psoriasis * porphyria * chronic kidney disease (stage iv or receiving dialysis) * known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \<1500) or thrombocytopenia (\<100 k) * concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen * known cirrhosis * known personal or family history of long qt syndrome * history of coronary artery disease with a history of graft or stent * history of heart failure, class 2 or greater using the new york heart association functional class * taking medications associated with prolonged qt and known risk of torsades de points. these medications may include some antipsychotic and antidepressant medications. (lopinavir-ritonavir platform) * taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial * taking warfarin (coumadin or jantoven) * known history of glucose-6-phosphate-dehydrogenase deficiency * history of myasthenia gravis

* known hypersensitivity to hcq or other 4-aminoquinoline compounds * known hypersensitivity to azithromycin or other azalide or macrolide antibiotics * currently hospitalized * signs of respiratory distress prior to randomization, including respiratory rate \>24 * current medications include hcq * concomitant use of other anti-malarial treatment or chemoprophylaxis * history of retinopathy of any etiology * psoriasis * porphyria * chronic kidney disease (stage iv or receiving dialysis) * known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \<1500) or thrombocytopenia (\<100 k) * concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen * known cirrhosis * known personal or family history of long qt syndrome * history of coronary artery disease with a history of graft or stent * history of heart failure, class 2 or greater using the new york heart association functional class * taking medications associated with prolonged qt and known risk of torsades de points. these medications may include some antipsychotic and antidepressant medications. (lopinavir-ritonavir platform) * taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial * taking warfarin (coumadin or jantoven) * known history of glucose-6-phosphate-dehydrogenase deficiency * history of myasthenia gravis

- known hypersensitivity to hcq or other 4-aminoquinoline compounds - known hypersensitivity to azithromycin or other azalide or macrolide antibiotics - currently hospitalized - signs of respiratory distress prior to randomization, including respiratory rate >24 - current medications include hcq - concomitant use of other anti-malarial treatment or chemoprophylaxis - history of retinopathy of any etiology - psoriasis - porphyria - chronic kidney disease (stage iv or receiving dialysis) - known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 k) - concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen - known cirrhosis - known personal or family history of long qt syndrome - history of coronary artery disease with a history of graft or stent - history of heart failure, class 2 or greater using the new york heart association functional class - taking medications associated with prolonged qt and known risk of torsades de points. these medications may include some antipsychotic and antidepressant medications. (lopinavir-ritonavir platform) - taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial - taking warfarin (coumadin or jantoven) - known history of glucose-6-phosphate-dehydrogenase deficiency - history of myasthenia gravis

- known hypersensitivity to hcq or other 4-aminoquinoline compounds - known hypersensitivity to azithromycin or other azalide or macrolide antibiotics - currently hospitalized - signs of respiratory distress prior to randomization, including respiratory rate >24 - current medications include hcq - concomitant use of other anti-malarial treatment or chemoprophylaxis - history of retinopathy of any etiology - psoriasis - porphyria - chronic kidney disease (stage iv or receiving dialysis) - known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 k) - concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen - known cirrhosis - known personal or family history of long qt syndrome - history of coronary artery disease with a history of graft or stent - history of heart failure, class 2 or greater using the new york heart association functional class - taking medications associated with prolonged qt and known risk of torsades de points. these medications may include some antipsychotic and antidepressant medications. (lopinavir-ritonavir platform) - taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial - taking warfarin (coumadin or jantoven) - known history of glucose-6-phosphate-dehydrogenase deficiency - history of myasthenia gravis